In this episode of Cholesterol Conversations, host Dr. Heather Johnson, Director of Preventive Cardiology for Women's Services at the Christine E. Lynn Women’s Health & Wellness Institute of Baptist Health South Florida, sits down with Dr. Viet T. Le, Associate Professor of Research and Co-Director of the Preventive Cardiology Clinic at Intermountain Medical Center in Utah. Together, they explore the latest advancements in LDL cholesterol management and discuss how clinicians can optimize risk assessment, treatment strategies, and patient adherence to improve cardiovascular outcomes.

From discussing the new AHA PREVENT calculator to strategies for overcoming statin intolerance and emerging lipid-lowering therapies, this podcast provides practical insights into treating and preventing cardiovascular disease in 2025 – in just 30 minutes!

🎧 Listen Now to stay ahead in lipid management and help patients achieve better heart health.

This activity has been approved for AMA PRA Category 1 Credit(s)™. After listening to the podcast discussion, go to Boston University Chobanian & Avedisian School of Medicine’s website: Cholesterol Conversations: Mastering LDL Management in 2025 | Chobanian & Avedisian School of Medicine/CCE.

Scroll down for more information about CME/CPE credits.

💡 For more educational content on LDL cholesterol management, visit: Vasculearn Network

Podcast Chapters:

1. Introduction & Overview (00:06 - 01:18)

2. Why is LDL Important? (01:18 - 03:47)

3. Risk Assessment & Screening Tools (03:47 - 08:39)

4. Special Risk Considerations (08:39 - 10:55)

5. Lipoprotein(a) & Additional Biomarkers (10:55 - 12:05)

6. Treatment Options: Statins & Beyond (12:05 - 17:24)

7. Overcoming Statin Intolerance (17:24 - 21:37)

8. Barriers to Treatment & Access Issues (21:37 - 25:00)

9. Future Directions & Emerging Therapies (25:00 - 28:23)

10. Final Takeaways (28:23 - 29:44)

Learning Objectives

At the end of this activity, the learner should be better able to:

• Describe current recommendations for LDL-C screening

• Identify patients at increased cardiovascular disease risk based on LDL-C levels

• Describe indications for initiation of statin and nonstatin therapies

• Identify barriers to therapy initiation and options for resolution

• Devise evidence-based strategies for optimal lipid management in primary prevention populations

Launch Date: 3/31/2025

Expiration Date: 3/30/2026

Joint Accreditation

In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and Vasculearn Network. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician CME Hours Boston University Chobanian & Avedisian School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Contact Hours: 0.5, all of which are eligible for pharmacology credits.

Pharmacist Contact Hours This activity is approved for 0.5 CPE credit(s) under the ACPE universal activity number JA0000185-9999-25-024-H01-P. The activity is available for credit claiming through March 30, 2026.

Speakers Disclosures

Dr. Heather Johnson, MD, MS Course Director

Disclosures: Dr. Johnson is a consultant for Amgen, Medtronic and Novartis. She is a consultant and a speaker for Esperion.

Viet Le, DMSc, MPAS, PA-C Podcast Speaker

Disclosures: Dr. Le is on the advisory board for Amarin, Amgen, Bayer, Idorsia, Lexicon, Merck, Novartis and Pfizer. He also receives grant research support from Johnson & Johnson and Janssen, Kardi and AliveCor and Novartis. 

Off-Label Discussion: will not be included. Accreditor Disclosures The following planning committee members from Boston University Chobanian & Avedisian School of Medicine’s Office of Continuing Medical Education have no relevant financial relationships with ineligible companies: Michael Burk, BS – Operations Manager; Deborah Whalen, APRN, MS, MBA - CNE Accreditation Reviewer.

John Fanikos, Rph, MBA                             Pharmacy Advisor

Disclosures: Dr. Fanikos is a consultant for Anthos Therapeutics. He is also a speaker and consultant for AstraZeneca and Pfizer. Boston University Chobanian & Avedisian School of Medicine Disclosure Policy Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.

How to Earn Credit and Obtain Your Certificate 

Physician CME Credits and Nursing CNE Education Credits: To successfully complete this activity, physicians and nurses are required to attend the live meeting and complete an evaluation on Boston University Chobanian & Avedisian School of Medicine’s Center for Continuing Education (BU CCE) website: Cholesterol Conversations: Mastering LDL Management in 2025 | Chobanian & Avedisian School of Medicine/CCE.

How to Request a CME and CNE Certificate By reviewing the course content and completing the evaluation, physicians are entitled to receive 0.5 Physician CME Hours, and nurses are entitled to receive 0.5 Nursing Contact Hours, all of which is eligible for pharmacology credit.  

After listening to the podcast discussion, the activity go to Boston University Chobanian & Avedisian School of Medicine’s website: Cholesterol Conversations: Mastering LDL Management in 2025 | Chobanian & Avedisian School of Medicine/CCE.

To receive a certificate for your participation in this activity, you will need to create an account on the CME Office's website and complete the evaluation survey. Then your certificate will be available for immediate download.

Requirements for Pharmacist CE Credit A program evaluation must be completed within 60 days of the live program date to receive CE credit.  Please refer to the evaluation instructions that follow for completing program evaluations.

Instructions for Completing a Program Evaluation and Earning CPE credit

1. After you have attended the live meeting go to the Boston University Chobanian & Avedisian School of Medicine’s Center for Continuing Education Learning Management System and create an account. Enter your ePID (license number) and choose American Council for Pharmacy Education in the Specialty Board section of your profile. This enables us to submit your credit to the CPE Monitor.

2. Complete the program evaluation and claim your certificate.  

• Log onto: Cholesterol Conversations: Mastering LDL Management in 2025 | Chobanian & Avedisian School of Medicine/CCE

• After registering your account, select “Take Course” button.

• Complete program evaluation and hit the “Next” button at the bottom of the screen.

• Then select your credit amount noting the correct participation minutes.

• You can then download an optional certificate for your records.

• You will receive a confirmation message of evaluation completion and notification that your CE data was reported to the CPE Monitor.

Please note: ACPE will only accept CPE data that is reported by providers within 60 days of the live program or completing the home-study. CPE data is reported immediately to the CPE Monitor upon your completion of this evaluation although it may take 48-72 hours to appear in your CPE Monitor profile.  You will be notified of any problems transmitting your participant data via email. Most transmission problems are related to errors in transcribing date of birth and/or NABP ID number. It is strongly recommended that you check your profile in the CPE Monitor to verify your participation in this program has been reported. CPE Monitor will reject CE data submitted after 60 days. *Your pharmacy license number and date of birth in order to report participant data to the CPE Monitor.  Pharmacy license numbers will not be used for any other purpose.

For questions about ACPE accreditation, contact Boston University Chobanian & Avedisian School of Medicine Center for Continuing Education at: [email protected].

Commercial Support

This program is supported through educational grants from Esperion Therapeutics Inc. and Merck & Co., Inc.

In this episode of Cholesterol Conversations, Drs. Marc Bonaca, Pam Taub, and Heather Johnson discuss how multiagent therapy can improve the provision of care in the real world. Covered topics include new data from the 2023 ACC Scientific Sessions on the efficacy of novel agents and the role of combination therapy, as well as the importance of shared decision-making and keys to managing high-risk populations.

In this episode of Cholesterol Conversations, join Drs. Neha Pagidipati, Christie Ballantyne, and Gregory Piazza for a roundtable discussion that addresses recent guidance on ASCVD management, current gaps in ASCVD care, patient barriers to LDL-C lowering, and nonstatin therapies to consider for  patients who don’t respond to statin therapy alone.